Destruction mechanisms of ozone over SARS-CoV-2.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
22 09 2021
Historique:
received: 01 12 2020
accepted: 23 08 2021
entrez: 23 9 2021
pubmed: 24 9 2021
medline: 9 10 2021
Statut: epublish

Résumé

In this pandemic SARS-CoV-2 crisis, any attempt to contain and eliminate the virus will also stop its spread and consequently decrease the risk of severe illness and death. While ozone treatment has been suggested as an effective disinfection process, no precise mechanism of action has been previously reported. This study aimed to further investigate the effect of ozone treatment on SARS-CoV-2. Therefore, virus collected from nasopharyngeal and oropharyngeal swab and sputum samples from symptomatic patients was exposed to ozone for different exposure times. The virus morphology and structure were monitored and analyzed through Atomic Force Microscopy (AFM), Transmission Electron Microscopy (TEM), Atomic Absorption Spectroscopy (AAS), and ATR-FTIR. The obtained results showed that ozone treatment not only unsettles the virus morphology but also alters the virus proteins' structure and conformation through amino acid disturbance and Zn ion release from the virus non-structural proteins. These results could provide a clearer pathway for virus elimination and therapeutics preparation.

Identifiants

pubmed: 34552128
doi: 10.1038/s41598-021-97860-w
pii: 10.1038/s41598-021-97860-w
pmc: PMC8458291
doi:

Substances chimiques

NSP10 protein, SARS-CoV-2 0
Viral Regulatory and Accessory Proteins 0
Ozone 66H7ZZK23N
Coronavirus RNA-Dependent RNA Polymerase EC 2.7.7.48
NSP12 protein, SARS-CoV-2 EC 2.7.7.48
Coronavirus Papain-Like Proteases EC 3.4.22.2
papain-like protease, SARS-CoV-2 EC 3.4.22.2
Zinc J41CSQ7QDS

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18851

Informations de copyright

© 2021. The Author(s).

Références

Biophys J. 1991 Oct;60(4):922-30
pubmed: 1742459
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Water Res. 2003 Apr;37(7):1443-67
pubmed: 12600374
Virology. 2009 Oct 25;393(2):265-71
pubmed: 19717178
J Virol. 2008 Mar;82(6):3000-10
pubmed: 18184703
Structure. 2002 Sep;10(9):1159-71
pubmed: 12220488
J Clin Invest. 2002 Mar;109(6):817-26
pubmed: 11901190
Curr Top Microbiol Immunol. 2005;287:57-94
pubmed: 15609509
Water Res. 2016 May 1;94:341-349
pubmed: 26971809
J Virol. 2003 Nov;77(22):11896-909
pubmed: 14581526
Langmuir. 2004 Dec 21;20(26):11713-20
pubmed: 15595802
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9436-41
pubmed: 26159422
Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9372-7
pubmed: 22635272
Infect Control Hosp Epidemiol. 2016 May;37(5):598-9
pubmed: 26818469
Biomolecules. 2014 Apr 17;4(2):419-34
pubmed: 24970223
Chem Biol. 2003 Aug;10(8):677-93
pubmed: 12954327
J Virol. 2015 Aug;89(16):8416-27
pubmed: 26041293
J Virol. 2006 Aug;80(16):7894-901
pubmed: 16873246
Science. 2020 May 15;368(6492):779-782
pubmed: 32277040
PLoS Pathog. 2010 Apr 22;6(4):e1000863
pubmed: 20421945
Lancet Microbe. 2020 May;1(1):e10
pubmed: 32835322
J Virol. 2005 Jan;79(2):696-704
pubmed: 15613297
J Med Virol. 2020 Sep;92(9):1567-1571
pubmed: 32232986
Sci Signal. 2020 Sep 29;13(651):
pubmed: 32994211
Antiviral Res. 2014 Sep;109:72-82
pubmed: 24992731
Oxid Med Cell Longev. 2014;2014:360438
pubmed: 24999379
J Biol Chem. 2010 Oct 22;285(43):33230-33241
pubmed: 20699222

Auteurs

Angila Ataei-Pirkooh (A)

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran.

Ali Alavi (A)

Department of Chemistry, Science and Research Branch, Islamic Azad University, Tehran, Iran.

Mehran Kianirad (M)

Department of Biotechnology, Iranian Research Organization for Science and Technology, Tehran, Iran.
Nano Fanavari Kian Gostar Company, Technologies Incubator Center, Iran University of Medical Sciences, Tehran, Iran.

Kowsar Bagherzadeh (K)

Stem Cell and Regenerative Medicine Research Center, Iran University of Medical, Tehran, Iran.
Eye Research Center, The Five Senses Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.

Alireza Ghasempour (A)

Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, 1449614535, Tehran, Iran.

Omid Pourdakan (O)

Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, 1449614535, Tehran, Iran.

Reza Adl (R)

Department of Chemistry, Faculty of Sciences, Shahid Beheshti University, Tehran, Iran.

Seyed Jalal Kiani (SJ)

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Mehdi Mirzaei (M)

Iran Ministry of Health and Medical Education, Deputy Ministry for Education, Tehran, Iran.

Bita Mehravi (B)

Nano Fanavari Kian Gostar Company, Technologies Incubator Center, Iran University of Medical Sciences, Tehran, Iran. mehravi.b@iums.ac.ir.
Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, 1449614535, Tehran, Iran. mehravi.b@iums.ac.ir.
Finetech in Medicine Research Center, Iran University of Medical, Tehran, Iran. mehravi.b@iums.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH